News
RXRX
3.315
+0.45%
0.015
Recursion updates financial calendar with upcoming first-quarter results and earnings call
PUBT · 1d ago
Press Release: Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
Dow Jones · 1d ago
Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell'
Seeking Alpha · 2d ago
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Seeking Alpha · 2d ago
Weekly Report: what happened at RXRX last week (0420-0424)?
Weekly Report · 3d ago
Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Its Recent Share Price Surge
Simply Wall St · 5d ago
AI-Driven Target Discovery Breakthrough Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX)
Simply Wall St · 6d ago
Assessing Recursion Pharmaceuticals (RXRX) Valuation After AI Webcast Highlights Drug Target Breakthrough
Simply Wall St · 04/23 05:05
Weekly Report: what happened at RXRX last week (0413-0417)?
Weekly Report · 04/20 10:08
Most shorted small cap stocks as of mid-April led by healthcare sector
Seeking Alpha · 04/17 19:29
Is Recursion Pharmaceuticals (RXRX) Turning Conference Spotlights Into a Durable AI Drug Discovery Edge?
Simply Wall St · 04/16 19:04
Largest borrow rate increases among liquid names
TipRanks · 04/14 12:46
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Recursion Pharmaceuticals (RXRX) and Johnson & Johnson (JNJ)
TipRanks · 04/14 11:41
Weekly Report: what happened at RXRX last week (0406-0410)?
Weekly Report · 04/13 10:11
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Investor Narratives Diverge On Future Potential
Simply Wall St · 04/10 21:28
Why Recursion (RXRX) Is Up 10.8% After Deepening Citeline Partnership To Power AI-Driven Clinical Trials
Simply Wall St · 04/09 14:23
Recursion Pharmaceuticals director Christopher Gibson disposes 40,000 shares for $124,000
Reuters · 04/08 20:59
Recursion director Blake Borgeson disposes of 30,000 shares for $93,000
Reuters · 04/08 20:58
Largest borrow rate increases among liquid names
TipRanks · 04/07 14:18
Weekly Report: what happened at RXRX last week (0330-0403)?
Weekly Report · 04/06 10:12
More
Webull provides a variety of real-time RXRX stock news. You can receive the latest news about Recursion Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.